Sheldon L. Koenig

Sheldon L. Koenig, listed as chief executive, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Esperion Therapeutics, Inc. and Portola Pharmaceuticals Inc. Between 31 January 2019 and 13 July 2026, the trades on record add up to 30 filings.

On the open market, the record shows 2 purchases worth €72k and 13 sales worth €610k. Sales outweigh purchases by €538k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 12 share grants. In 2026 alone, the filings show no purchases and 2 sales.

The latest filing, published on 13 July 2026, reports a transaction in Esperion Therapeutics, Inc. The clock since the last published purchase (10 May 2023) now reads 1,263 days. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.